Zacytuj

1. D. McTavish, K. L. Goa and M. Ferrill, Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy, Drugs39 (1990) 552–574; https://doi.org/10.2165/00003495-199039040-0000610.2165/00003495-199039040-00006Search in Google Scholar

2. F. Register, Proposal to withdraw approval of two new drug applications and one abbreviated new drug application; opportunity for a hearing. Food and Drug Administration [Docket No. 96N-0512], Federal Register62 (1997) 2–9.Search in Google Scholar

3. T. J. MacConnell and A. J. Stanners, Torsades de pointes complicating treatment with terfenadine, BMJ302 (1991) 1469; https://doi.org/10.1136/bmj.302.6790.1469-b10.1136/bmj.302.6790.1469-bSearch in Google Scholar

4. K. Kamiya, R. Niwa, M. Morishima, H. Honjo and M. C. Sanguinetti, Molecular determinants of hERG channel block by terfenadine and cisapride, J. Pharmacol. Sci. 108 (2008) 301–307; https://doi.org/10.1254/jphs.08102fp10.1254/jphs.08102FPSearch in Google Scholar

5. H. R. Lu, A. N. Hermans and D. J. Gallacher, Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?, Br. J. Pharmacol. 166 (2012) 1490–1502; https://doi.org/10.1111/j.1476-5381.2012.01880.x10.1111/j.1476-5381.2012.01880.xSearch in Google Scholar

6. C. Valenzuela, E. Delpon, L. Franqueza, P. Gay, J. Vicente and J. Tamargo, Comparative effects of nonsedating histamine H1 receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels, Eur. J. Pharmacol. 326 (1997) 257–263; https://doi.org/10.1016/s0014-2999(97)85421-010.1016/S0014-2999(97)85421-0Search in Google Scholar

7. I. S. Chen, C. Liu, M. Tateyama, I. Karbat, M. Uesugi, E. Reuveny and Y. Kubo, Non-sedating antihistamines block G-protein-gated inwardly rectifying K(+) channels, Br. J. Pharmacol. 176 (2019) 3161–3179; https://doi.org/10.1111/bph.1471710.1111/bph.14717669264031116876Search in Google Scholar

8. E. Hadzijusufovic, B. Peter, K. V. Gleixner, K. Schuch, W. F. Pickl, T. Thaiwong, V. Yuzbasiyan-Gurkan, I. Mirkina, M. Willmann and P. Valent, H1-receptor antagonists terfenadine and lorata-dine inhibit spontaneous growth of neoplastic mast cells, Exp. Hematol. 38 (2010) 896–907; https://doi.org/10.1016/j.exphem.2010.05.00810.1016/j.exphem.2010.05.008433797120570632Search in Google Scholar

9. F. Nicolau-Galmes, A. Asumendi, E. Alonso-Tejerina, G. Perez-Yarza, S. M. Jangi, J. Gardeazabal, Y. Arroyo-Berdugo, J. M. Careaga, J. L. Diaz-Ramon, A. Apraiz and M. D. Boyano, Terfenadine induces apoptosis and autophagy in melanoma cells through ROS-dependent and -independent mechanisms, Apoptosis16 (2011) 1253–1267; https://doi.org/10.1007/s10495-011-0640-y10.1007/s10495-011-0640-y320400121861192Search in Google Scholar

10. W. T. Wang, Y. H. Chen, J. L. Hsu, W. J. Leu, C. C. Yu, S. H. Chan, Y. F. Ho, L. C. Hsu and J. H. Guh, Terfenadine induces anti-proliferative and apoptotic activities in human hormone-refractory prostate cancer through histamine receptor-independent Mcl-1 cleavage and Bak up-regulation, Naunyn Schmiedebergs Arch. Pharmacol. 387 (2014) 33–45; https://doi.org/10.1007/s00210-013-0912-x10.1007/s00210-013-0912-x24048439Search in Google Scholar

11. P. Fernandez-Nogueira, A. Noguera-Castells, G. Fuster, L. Recalde-Percaz, N. Moragas, A. Lopez-Plana, E. Enreig, P. Jauregui, N. Carbo, V. Almendro, P. Gascon, P. Bragado and M. Mancino, Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer, Cancer Lett. 424 (2018) 70–83; https://doi.org/10.1016/j.canlet.2018.03.01410.1016/j.canlet.2018.03.01429548821Search in Google Scholar

12. L. An, D. D. Li, H. X. Chu, Q. Zhang, C. L. Wang, Y. H. Fan, Q. Song, H. D. Ma, F. Feng and Q. C. Zhao, Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal, Pharmacol. Res. 124 (2017) 105–115; https://doi.org/10.1016/j.phrs.2017.07.02110.1016/j.phrs.2017.07.02128754458Search in Google Scholar

13. H. Hibino, A. Inanobe, K. Furutani, S. Murakami, I. Findlay and Y. Kurachi, Inwardly rectifying potassium channels: their structure, function, and physiological roles, Physiol. Rev. 90 (2010) 291–366; https://doi.org/10.1152/physrev.00021.200910.1152/physrev.00021.200920086079Search in Google Scholar

14. P. Sulaiman, Y. Xu, M. E. Fina, S. R. Tummala, H. Ramakrishnan, A. Dhingra and N. Vardi, Kir2.4 surface expression and basal current are affected by heterotrimeric G-proteins, J. Biol. Chem. 288 (2013) 7420–7429; https://doi.org/10.1074/jbc.M112.41279110.1074/jbc.M112.412791359164923339194Search in Google Scholar

15. C. D. Ji, Y. X. Wang, D. F. Xiang, Q. Liu, Z. H. Zhou, F. Qian, L. Yang, Y. Ren, W. Cui, S. L. Xu, X. L. Zhao, X. Zhang, Y. Wang, P. Zhang, J. M. Wang, Y. H. Cui and X. W. Bian, Kir2.1 Interaction with Stk38 promotes invasion and metastasis of human gastric cancer by enhancing MEKK2-MEK1/2-ERK1/2 signaling, Cancer Res. 78 (2018) 3041–3053; https://doi.org/10.1158/0008-5472.CAN-17-377610.1158/0008-5472.CAN-17-3776811178829549164Search in Google Scholar

16. H. Liu, J. Huang, J. Peng, X. Wu, Y. Zhang, W. Zhu and L. Guo, Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway, Mol. Cancer14 (2015) 59; https://doi.org/10.1186/s12943-015-0298-010.1186/s12943-015-0298-0437312825880778Search in Google Scholar

17. I. Lee, S. J. Lee, T. M. Kang, W. K. Kang and C. Park, Unconventional role of the inwardly rectifying potassium channel Kir2.2 as a constitutive activator of RelA in cancer, Cancer Res. 73 (2013) 1056–1062; https://doi.org/10.1158/0008-5472.CAN-12-249810.1158/0008-5472.CAN-12-249823269273Search in Google Scholar

18. X. Y. Wu and X. Y. Yu, Overexpression of KCNJ4 correlates with cancer progression and unfavorable prognosis in lung adenocarcinoma, J. Biochem. Mol. Toxicol. 33 (2019) e22270; https://doi.org/10.1002/jbt.2227010.1002/jbt.2227030512237Search in Google Scholar

19. M. A. van der Heyden, A. Stary-Weinzinger and J. A. Sanchez-Chapula, Inhibition of cardiac inward rectifier currents by cationic amphiphilic drugs, Curr. Mol. Med. 13 (2013) 1284–1298; https://doi.org/10.2174/1566524011313999004310.2174/1566524011313999004323448372Search in Google Scholar

20. P. Thomas and T. G. Smart, HEK293 cell line: a vehicle for the expression of recombinant proteins, J. Pharmacol. Toxicol. Methods. 51 (2005) 187–200; https://doi.org/10.1016/j.vascn.2004.08.01410.1016/j.vascn.2004.08.01415862464Search in Google Scholar

21. X. Du, H. Zhang, C. Lopes, T. Mirshahi, T. Rohacs and D. E. Logothetis, Characteristic interactions with phosphatidylinositol 4,5-bisphosphate determine regulation of kir channels by diverse modulators, J. Biol. Chem. 279 (2004) 37271–37281; https://doi.org/10.1074/jbc.M40341320010.1074/jbc.M40341320015155739Search in Google Scholar

22. S. Przestalski, J. Sarapuk, H. Kleszczynska, J. Gabrielska, J. Hladyszowski, Z. Trela and J. Kuczera, Influence of amphiphilic compounds on membranes, Acta Biochim. Pol. 47 (2000) 627–638.10.18388/abp.2000_3984Search in Google Scholar

23. J. J. Babcock and M. Li, hERG channel function: beyond long QT, Acta Pharmacol. Sin. 34 (2013) 329–335; https://doi.org/10.1038/aps.2013.610.1038/aps.2013.6358791523459091Search in Google Scholar

24. G. D’Alessandro, M. Catalano, M. Sciaccaluga, G. Chece, R. Cipriani, M. Rosito, A. Grimaldi, C. Lauro, G. Cantore, A. Santoro, B. Fioretti, F. Franciolini, H. Wulff and C. Limatola, KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo, Cell Death Dis. 4 (2013) e773; https://doi.org/10.1038/cddis.2013.27910.1038/cddis.2013.279376344123949222Search in Google Scholar

25. M. Nunez, V. Medina, G. Cricco, M. Croci, C. Cocca, E. Rivera, R. Bergoc and G. Martin, Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDAMB-231, BMC Pharmacol. Toxicol. 14 (2013) 6; https://doi.org/10.1186/2050-6511-14-610.1186/2050-6511-14-6355838623311706Search in Google Scholar

eISSN:
1846-9558
Język:
Angielski
Częstotliwość wydawania:
4 razy w roku
Dziedziny czasopisma:
Pharmacy, other